No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study

ObjectiveTo study the efficacy of interval debulking surgery (IDS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) compared to IDS alone for the treatment of ovarian cancer after neoadjuvant chemotherapy (NACT).MethodsWe conducted a retrospective study of patients with stage IIIC/IV high-grad...

Full description

Bibliographic Details
Main Authors: Mengmeng Lyu, Jin Lu, Yang Shen, Qianqian Chen, Fei Deng, Jinhua Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Surgery
Subjects:
HIPEC
ovarian cancer
interval debulking
neoadjuvant chemotherapy
retrospective
Online Access:https://www.frontiersin.org/articles/10.3389/fsurg.2022.997344/full

Internet

https://www.frontiersin.org/articles/10.3389/fsurg.2022.997344/full

Similar Items